Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Preterm birth and low birthweights were more common among infants born to women with HIV, but the infants were no more likely to die.
Aim is to reduce viral load in those infected in order to put brake on spread
People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.
HIV-positive women who breastfeed can protect their infants from infection for a year after birth by giving them a liquid form of PrEP.
A two-drug regimen of Norvir (ritonavir)Ã¢€“boosted Reyataz (atazanavir) and Epivir (lamivudine) treats HIV as well or better tha...
Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.
Research of Bristol-Myers Squibb’s BMS-955176, an HIV maturation inhibitor, has shown the antiretroviral is potent and well-tolerated.
Medications used to boost the levels of other HIV antiretrovirals are the most likely out of all ARVs to have dangerous interactions with...
An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...
The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...
Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired...
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.